Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $525.1 million.

  • Ligand Pharmaceuticals' Short-term Investments rose 23658.03% to $525.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $525.1 million, marking a year-over-year increase of 23658.03%. This contributed to the annual value of $183.9 million for FY2024, which is 2477.21% up from last year.
  • Ligand Pharmaceuticals' Short-term Investments amounted to $525.1 million in Q3 2025, which was up 23658.03% from $177.4 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Short-term Investments peaked at $525.1 million during Q3 2025, and registered a low of $117.3 million during Q3 2022.
  • Moreover, its 5-year median value for Short-term Investments was $189.0 million (2022), whereas its average is $221.1 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Short-term Investments crashed by 6087.44% in 2022, and later skyrocketed by 23658.03% in 2025.
  • Ligand Pharmaceuticals' Short-term Investments (Quarter) stood at $321.6 million in 2021, then crashed by 48.11% to $166.9 million in 2022, then decreased by 11.69% to $147.4 million in 2023, then grew by 24.77% to $183.9 million in 2024, then skyrocketed by 185.63% to $525.1 million in 2025.
  • Its Short-term Investments was $525.1 million in Q3 2025, compared to $177.4 million in Q2 2025 and $160.9 million in Q1 2025.